For the second year in a row, Part D plans and manufacturers are entering uncharted territory as contracting discussions for Plan Year (PY) 2026 get underway. PY 2026 will be the second year of the Inflation Reduction Act’s (IRA) major Part D redesign changes which are reshaping the Part D landscape. Currently, plans, manufacturers and other stakeholders have limited insight into how Part D redesign will affect costs and utilization starting in January 2025 as Part D redesign takes effect.   2026 will also mark the first year of implementation of Maximum Fair Prices (MFPs) for the first ten selected drugs, adding new contracting dynamics for these drugs and their therapeutic competitors. Anticipating the combined impacts of Part D benefit redesign interacted with MFP implementation will inform successful contracting strategies for PY 2026.

In this webinar, Avalere experts will discuss the likely impacts of the second year of the IRA’s Part D changes on manufacturers, Part D plans, and the broader market. Panelists will focus on PY 2026 plan-manufacturer contracting negotiations and will address topics including:

• How the IRA’s Medicare Part D benefit redesign influenced PY 2025 plan offerings
• How Part D redesign combined with Medicare negotiation may influence plan formulary strategies for MFP products vs. non-negotiated competitors
• How continued shifts in the market for standalone Prescription Drug Plan (PDP) and Medicare Advantage Prescription Drug (MA-PD) plans may impact PY 2026 contracting strategies